Entities / Company
Gilead Sciences.
American company
- Reports this week
- 3
- Active events
- 3
- Connections
- 308
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.Some support4 reports
-
A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.Some support1 report
-
MarketBeat listed Danaher, Dexcom, Medtronic, Gilead Sciences, and Boston Scientific as stocks to watch on September 22, 2026.Some support1 report
Earlier this month
-
Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.Some support1 report
-
Gilead Sciences established a strategic alliance and contributed $5 billion, while Lakefront Biotherapeutics acquired assets from Ouro Medicines.Some support1 report
-
Gilead Sciences and T. Rowe Price are currently among the largest dividend payers.Some support1 report
-
Analyst upgrades and downgrades were noted for General Motors, Gilead Sciences, Emerson Electric, and CrowdStrike on May 22, 2026.Some support1 report
-
A conference involving Gilead Sciences and Bayer was held in Philadelphia on September 10, 2026.Some support1 report
-
Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.Some support1 report
-
Merdad Parsey, formerly of Gilead Sciences, joined the Sofinnova investment team.Some support1 report
-
Gilead Sciences product acceptance paves way for market access, guided by expert opinion in NHS Scotland.Some support1 report
-
Gilead Sciences and Grifols traded on the NASDAQ stock exchange on September 8, 2026.Some support1 report
-
GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.Speculative1 report1 development inside
-
Gilead Sciences provided an HIV prevention drug consignment to a Zambian hospital, funded by the US.Some support1 report
-
Executive leadership experience gained at Gilead Sciences, involving Cocrystal Pharma.Some support1 report
One to three months ago
-
FDA granted designation for a drug under Gibbs' leadership, involving GSK and Gilead Sciences.Some support1 report
-
Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.Some support1 report
-
Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.Some support1 report
-
McDonald's, Walmart, and Gilead Sciences are suggested as resilient safe-haven investments during market turmoil.Some support2 reports
-
A lawsuit has been filed regarding the importation of foreign-market drugs, involving Gilead Sciences and Meritain Health, Inc.Some support3 reports1 development inside
-
A U.S. patient case involving Gilead Sciences originated in Turkey, concerning revenue protection from generic imports.Some support1 report
-
Collaboration revenue streams are shared between Sanofi and Gilead Sciences.Some support1 report
-
MarketBeat is providing analyst recommendations and comparing two healthcare companies, Gilead Sciences and Pharvaris.Some support2 reports
-
Gilead Sciences reported earnings, leading Bank of America to reiterate a Buy rating.Some support1 report
-
Gilead Sciences, Boston Scientific, McKesson Corporation, and Dexcom are listed as top medical stocks.Some support3 reports
-
Norges Bank acquired a new stake in Gilead Sciences, while Boston Partners also bought shares, all filed with the SEC.Some support1 report
-
Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.Some support1 report
-
Benzinga reports on market expectations for Amgen, Pfizer, and Gilead Sciences.Some support2 reports
-
Top holdings of the IBBQ and IXJ funds were reported, featuring major pharmaceutical companies.Some support3 reports
-
Gilead Sciences sponsored a session at the ESSENCE Festival.Some support1 report
-
The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.Well supported9 reports
-
Bristol-Myers Squibb and Gilead Sciences are major biopharma firms, with Gilead Sciences recently employing Lena Moran-Adams.Some support1 report
-
HSBC upgraded Gilead Sciences stock, citing pessimistic consensus.Some support1 report
-
Gilead Sciences received FDA approval and preferred status via NCC review for its drug Trodelvy.Some support1 report
-
An investor made multiple stock purchases in companies including Cencora, Gilead Sciences, GE Aerospace, and American Express.Some support1 report
-
Norges Bank acquired a new position in Gilead Sciences shares, triggering institutional ownership filing requirements with the SEC.Some support1 report
Gone quiet
No new reports in 90+ days-
Gilead Sciences received FDA endorsement and product approvals in Norway, Iceland, and Liechtenstein on August 27, 2025, while navigating Trump's tariffs.Well supported3 reports
-
Gilead Sciences' drug Trodelvy received marketing authorization from the European Commission for use in EU member states.Some support1 report
-
Gilead Sciences filed its required 13F reports with the Securities and Exchange Commission on June 22, 2026.Some support1 report
-
Phase 3 results showed efficacy in primary biliary cholangitis involving Alp and Gilead Sciences.Some support1 report
-
Gilead Sciences supports Native Son Awards featuring Terrell Carter, with a fellowship debut scheduled in New York.Some support1 report
-
Benzinga generated content regarding the financial performance of Gilead Sciences on June 17, 2026.Some support1 report
-
Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.Some support1 report
-
Cantor Fitzgerald issued research notes on Gilead Sciences (GILD) stock, which are being aggregated by MarketBeat.Some support1 report
-
Multiple investment firms, including Paulson Wealth Management and Alpha Cubed Investments, have made various transactions regarding their holdings in Gilead Sciences.Some support1 report
-
Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.Some support1 report1 development inside
-
Westfield Capital Management acquired a new stake in Gilead Sciences shares, concurrent with an SEC filing on June 6, 2026.Some support1 report
-
Gilead Sciences developed Yeytuo for HIV prevention, which received authorization from the European Commission following EMA assessment.Some support2 reports
-
U.S. purchases PEPFAR doses and Gilead sells drugs at no profit following Trump administration's foreign aid cuts.Some support2 reports
-
Incyte and Gilead Sciences are discussed in the context of commercializing innovative medicines for life-threatening diseases.Some support2 reports
-
Gilead Sciences holds the largest shareholder stake in Assembly Biosciences, followed by Alexander Schornstein and The Vanguard Group.Speculative1 report
-
FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.Speculative1 report1 development inside
-
Kymera entered an exclusive option and license agreement with Gilead Sciences.Some support6 reports
-
Gilead Sciences is identified as a participant within the broader medical sector.Speculative2 reports
-
Zacks listed Gilead Sciences as a trending stock, noting that industry performance influences stock trends.Some support2 reports2 developments inside
-
Gilead Sciences stock declined by 3.1% while the broader industry gained 3.2% on June 27, 2025.Speculative1 report
-
The FDA approved a new PrEP formulation from Gilead Sciences on June 27, 2025, noting the disproportionate impact of HIV in sub-Saharan Africa.Speculative1 report
-
Joshua Britton founded Debut, a company listed among influential firms.Speculative1 report
-
Supreme Court ruling upholds the status of HIV PrEP drugs.Speculative1 report
-
The U.S. Supreme Court upheld an ACA provision requiring insurer coverage, sustaining prescription volumes.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Gilead Sciences this week
News at the entities that move Gilead Sciences most-
Norges Bank TransactionalNorges Bank bought a new position in Qualcomm shares, coinciding with buy ratings and price targets from TD Cowen, reported by MarketBeat.Moves Gilead Sciences
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Gilead Sciences
-
European Commission StructuralA European Commission summit focused on strategic cooperation, minerals, and pivoting away from the United States toward the EU.Moves Gilead Sciences
-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves Gilead Sciences
-
Merck StructuralEli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Moves Gilead Sciences
-
Invesco StructuralInvesco manages the S&P 500 Quality ETF, and Microsoft is identified as a major holding within this fund.Moves Gilead Sciences
Connections
The 40 strongest of 308, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Arcellx Structural
Arcellx was acquired by Gilead Sciences in a definitive transaction to integrate its technology into Gilead's portfolio.
-
Kymera Therapeutics Operational
Kymera Therapeutics and Gilead Sciences have entered an exclusive license agreement to co-develop and commercialize molecular glue degraders for cancer.
-
FDA Structural
The FDA exercises ultimate authority over Gilead's drug development, trials, and market access through approvals, holds, and orders.
-
Anu Osinusi Structural
Anu Osinusi is employed as VP of Clinical Development at Gilead Sciences.
-
European Commission Structural
The European Commission grants marketing authorization and regulates Gilead Sciences' pharmaceutical products.
-
Eli Lilly and Company Operational
Eli Lilly and Gilead Sciences actively compete against each other in the global pharmaceutical market.
-
Merck Structural
Gilead relies on Merck's products for combination therapies and the companies are actively partnering on new drug development.
-
Invesco Structural
Invesco maintains a large investment position in Gilead Sciences.
Show all 40 connections
-
Compugen Ltd. Transactional
Compugen licensed the drug candidate GS-0321 to Gilead for development following a partnership agreement.
-
Assembly Biosciences (United States) Structural
Gilead Sciences holds the largest shareholder stake and provides funding, licensing rights, and development partnerships to Assembly Biosciences.
-
Ideaya Biosciences (United States) Structural
Gilead supplies Trodelvy to Ideaya Biosciences, and the companies are collaborating on clinical trials.
-
Pfizer Operational
Pfizer and Gilead Sciences actively compete in the fragmented HIV drug market.
-
Galapagos Structural
Galapagos and Gilead Sciences maintain a structural relationship defined by a transformational agreement and board representation.
-
Securities and Exchange Commission Structural
Gilead Sciences is subject to formal regulatory oversight and filing requirements imposed by the Securities and Exchange Commission.
-
Food and Drug Administration Structural
The FDA formally regulates Gilead Sciences, issuing clinical holds and granting product approvals.
-
Moderna Operational
The companies are major players in the biotech sector and actively compete in the market.
-
SEC Structural
Gilead Sciences is subject to regulatory oversight and disclosure requirements enforced by the SEC.
-
SPDR Structural
SPDR holds Gilead Sciences as a major investment position in its assets.
-
Sanofi Operational
The two companies are engaged in an active collaboration where revenue streams are shared.
-
Bristol-Myers Squibb Operational
The two companies are major biopharma competitors, actively vying for market share in specialized therapeutic areas like TIGIT-blocking.
-
Merck KGaA Operational
The two companies are current competitors in the fragmented HIV drug market and share a history of collaboration.
-
McKesson Corporation Structural
McKesson acts as a distributor in the supply chain for pharmaceutical products manufactured by Gilead Sciences.
-
Boston Partners Transactional
Boston Partners purchased a new stake in Gilead Sciences shares.
-
National Comprehensive Cancer Network Operational
NCC review directly influences the preferred status of Gilead's drugs.
-
ABR Mentioned together
ABR tracks and validates financial metrics and brokerage recommendations related to Gilead Sciences.
-
Bank of America Operational
Bank of America provides investment ratings on Gilead Sciences based on its financial performance.
-
World Health Organization Structural
Gilead leverages WHO prequalification processes and partners with global health initiatives to deliver medications.
-
Biogen Operational
The two companies are recognized as peers and actively compete within the therapeutics market.
-
Centers for Disease Control and Prevention Operational
Gilead Sciences uses CDC estimates to track and compare its usage data.
-
Norges Bank Transactional
Norges Bank acquired a new investment stake in Gilead Sciences shares.
-
Flagship Pioneering Transactional
ProFound Therapeutics formed by Flagship Pioneering.
-
Dexcom Mentioned together
Both Dexcom and Gilead Sciences are listed together as top medical stocks.
-
Cynthia Levy Operational
Cynthia Levy provides professional support for specific research outcomes of Gilead Sciences.
-
Walmart Mentioned together
The evidence suggests that both companies are cited together as examples of safe-haven investments.
-
Gibbs Transactional
Gibbs was employed by Gilead Sciences for a period of 20 years.
-
Cocrystal Pharma Mentioned together
A historical personnel link was observed, indicating an executive gained experience at Gilead Sciences.
-
Jim Cramer Mentioned together
Jim Cramer provides commentary on the biotech sector, which includes Gilead Sciences.
-
Biotech Mentioned together
Gilead Sciences is cited as a member of the Biotech sector.
-
Vertex Pharmaceuticals Operational
Both companies are identified as major competitors operating in the biotechnology sector.
-
MarketBeat Mentioned together
MarketBeat tracks and provides consensus ratings and stock watch status for Gilead Sciences.
History
Events by the month they beganSeptember 2026
12 events- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
- MarketBeat listed Danaher, Dexcom, Medtronic, Gilead Sciences, and Boston Scientific as stocks to watch on September 22, 2026.
- Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.
- Gilead Sciences established a strategic alliance and contributed $5 billion, while Lakefront Biotherapeutics acquired assets from Ouro Medicines.
- Gilead Sciences and T. Rowe Price are currently among the largest dividend payers.
- Analyst upgrades and downgrades were noted for General Motors, Gilead Sciences, Emerson Electric, and CrowdStrike on May 22, 2026.
- A conference involving Gilead Sciences and Bayer was held in Philadelphia on September 10, 2026.
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- Merdad Parsey, formerly of Gilead Sciences, joined the Sofinnova investment team.
- Gilead Sciences product acceptance paves way for market access, guided by expert opinion in NHS Scotland.
- Gilead Sciences and Grifols traded on the NASDAQ stock exchange on September 8, 2026.
- Gilead Sciences provided an HIV prevention drug consignment to a Zambian hospital, funded by the US.
August 2026
14 events- Executive leadership experience gained at Gilead Sciences, involving Cocrystal Pharma.
- FDA granted designation for a drug under Gibbs' leadership, involving GSK and Gilead Sciences.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.
- McDonald's, Walmart, and Gilead Sciences are suggested as resilient safe-haven investments during market turmoil.
- A lawsuit has been filed regarding the importation of foreign-market drugs, involving Gilead Sciences and Meritain Health, Inc.
- A U.S. patient case involving Gilead Sciences originated in Turkey, concerning revenue protection from generic imports.
- Collaboration revenue streams are shared between Sanofi and Gilead Sciences.
- MarketBeat is providing analyst recommendations and comparing two healthcare companies, Gilead Sciences and Pharvaris.
- Gilead Sciences reported earnings, leading Bank of America to reiterate a Buy rating.
- Gilead Sciences, Boston Scientific, McKesson Corporation, and Dexcom are listed as top medical stocks.
- Norges Bank acquired a new stake in Gilead Sciences, while Boston Partners also bought shares, all filed with the SEC.
- Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.
- Benzinga reports on market expectations for Amgen, Pfizer, and Gilead Sciences.
July 2026
7 events- Top holdings of the IBBQ and IXJ funds were reported, featuring major pharmaceutical companies.
- Gilead Sciences sponsored a session at the ESSENCE Festival.
- Bristol-Myers Squibb and Gilead Sciences are major biopharma firms, with Gilead Sciences recently employing Lena Moran-Adams.
- HSBC upgraded Gilead Sciences stock, citing pessimistic consensus.
- Gilead Sciences received FDA approval and preferred status via NCC review for its drug Trodelvy.
- An investor made multiple stock purchases in companies including Cencora, Gilead Sciences, GE Aerospace, and American Express.
- Norges Bank acquired a new position in Gilead Sciences shares, triggering institutional ownership filing requirements with the SEC.
Show 1 earlier month
June 2026
27 events- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.
- Gilead Sciences received FDA endorsement and product approvals in Norway, Iceland, and Liechtenstein on August 27, 2025, while navigating Trump's tariffs.
- Gilead Sciences' drug Trodelvy received marketing authorization from the European Commission for use in EU member states.
- Gilead Sciences filed its required 13F reports with the Securities and Exchange Commission on June 22, 2026.
- Phase 3 results showed efficacy in primary biliary cholangitis involving Alp and Gilead Sciences.
- Gilead Sciences supports Native Son Awards featuring Terrell Carter, with a fellowship debut scheduled in New York.
- Benzinga generated content regarding the financial performance of Gilead Sciences on June 17, 2026.
- Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.
- Cantor Fitzgerald issued research notes on Gilead Sciences (GILD) stock, which are being aggregated by MarketBeat.
- Multiple investment firms, including Paulson Wealth Management and Alpha Cubed Investments, have made various transactions regarding their holdings in Gilead Sciences.
- Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.
- Westfield Capital Management acquired a new stake in Gilead Sciences shares, concurrent with an SEC filing on June 6, 2026.
- Gilead Sciences developed Yeytuo for HIV prevention, which received authorization from the European Commission following EMA assessment.
- U.S. purchases PEPFAR doses and Gilead sells drugs at no profit following Trump administration's foreign aid cuts.
- Incyte and Gilead Sciences are discussed in the context of commercializing innovative medicines for life-threatening diseases.
- Gilead Sciences holds the largest shareholder stake in Assembly Biosciences, followed by Alexander Schornstein and The Vanguard Group.
- FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.
- Kymera entered an exclusive option and license agreement with Gilead Sciences.
- Gilead Sciences is identified as a participant within the broader medical sector.
- Zacks listed Gilead Sciences as a trending stock, noting that industry performance influences stock trends.
- Gilead Sciences stock declined by 3.1% while the broader industry gained 3.2% on June 27, 2025.
- The FDA approved a new PrEP formulation from Gilead Sciences on June 27, 2025, noting the disproportionate impact of HIV in sub-Saharan Africa.
- Joshua Britton founded Debut, a company listed among influential firms.
- Supreme Court ruling upholds the status of HIV PrEP drugs.
- The U.S. Supreme Court upheld an ACA provision requiring insurer coverage, sustaining prescription volumes.